Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Metsä Group conducted its second Ethics Barometer to measure the responsibility of its corporate culture

Metsä Group press release 22 September 2022A responsible corporate culture is one of Metsä Group’s 2030 sustainability objectives. According to the results of our second Ethics Barometer, which measures our progress towards the objective, we have improved in nearly every area since the 2020 barometer. More than 5,600 Metsä Group employees responded to the survey. Several development measures will now be launched to further develop the ethics of our operations. “We’re interested in matters that are topical at our sites and relevant to our corporate culture from ethical perspective. We

Restructuring of the Synnersten family’s ownership in Arla Plast

Arla Plast AB (“Arla Plast” or the “Company”) announces that the Synnersten family’s investment company, Synnersten Invest AB (“Synnersten Invest”), today has resolved on, and carried out, a distribution of all shares held by Synnersten Invest in Arla Plast to the shareholders of Synnersten Invest.All shares in Synnersten Invest are held by Kenneth Synnersten, Chairman of the Board of Arla Plast, Annelie Arnbäck, member of the Board of Arla Plast, Jan Synnersten, member of the Board of Arla Plast, and Mats Synnersten, through their respective wholly-owned companies. Before the

Viaplay and Dag Johan Haugerud partner for ‘Sex Dreams Love’ film trilogy

· Three Norwegian films by celebrated director Dag Johan Haugerud (‘Beware of Children’) explore sexuality, longing and transgression in modern Nordic society · Trilogy produced by Motlys and distributed by Arthaus · Viaplay to premiere at least 70 Originals in 2022 Dag Johan Haugerud, one of Norway’s most acclaimed directors, will team up with Viaplay to create three interconnected films that explore themes of sexuality, longing and transgression in modern Nordic society. ‘Sex’, ‘Dreams’ and ‘Love’ will feature all-star Norwegian casts and will premiere on Viaplay in 2024

Sortera acquires RGS Nordic AB

Sortera strengthens its position in the soil decontamination market through the acquisition of RGS Nordic’s Swedish operations.The Swedish operations, with 74 employees and a turnover of 500 million SEK, are done through the company RGS Nordic AB with facilities for reception and treatment of contaminated soil and construction waste in Malmö, Gothenburg, Stockholm and Norrköping. The company also offers on-site treatment of contaminated soil and water. The acquisition will consolidate Sortera’s position as one of the market leaders in soil decontamination on the Swedish market. RGS

BioStock Investor Meeting: Arcede Pharma presents

At the end of June this year, following the spin-off from Respiratorius, trading in Arcede Pharma began on Spotlight. At the helm is CEO Mia Lundblad, who came to the BioStock Investor Meeting to talk about Arcede’s COPD and asthma project RCD45. She also talked about what’s next to come for the company.Read the full article at biostock.se:https://www.biostock.se/en/2022/09/biostock-investor-meeting-arcede-pharma-presents/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Cantargia reports first non-squamous NSCLC patient treated with nadunolimab, Keytruda® and chemotherapy

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that the first patient has been treated in a new arm of the phase Ib clinical trial CIRIFOUR. The new arm adds Cantargia’s lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), to the recently established first line therapy for non-small cell lung cancer (NSCLC). Up to 24 non-squamous NSCLC patients will be treated with a combination of nadunolimab, the checkpoint inhibitor Keytruda® (pembrolizumab) and platinum-based chemotherapy. The objective is to assess safety, efficacy, and biomarkers.“We are thrilled to advance

Atlas Copco’s Capital Markets Day, November 17, 2022

Stockholm, Sweden, September 22, 2022: Atlas Copco invites investors, analysts, media, and other key stakeholders to its Capital Markets Day on November 17, 2022. The Capital Markets Day will be held as a physical event in Stockholm, Sweden.The purpose of the Capital Markets Day is to give an update on the strategy and development of the Atlas Copco Group and its worldwide operations. In addition, this year, participants will get a more in-depth understanding of the Vacuum Technique and Industrial Technique business areas. The first part of the Capital Markets Day will be held at Quality

CS MEDICA provides patent update

CS MEDICA (”CS MEDICA” or the ”Company”) announces today that the Company has completed all PCT continuation patents, in total 7 patents applications covering 11 products.CS MEDICA strives toward granting patent acceptance on all present and future treatment products. All CS MEDICA’s treatment products (topical and oral) as of today are patented in accordance with PCT (Patent Cooperation Treaty), covering 153 nations across the globe. The Company currently has seven proceeding patents that are filed and pending. The 15[th] of September 2022 the USA national patent application on Arthritis &

HC Andersen Capital Events 22.09.22: Meet the top management in InDex Pharmaceuticals

HC Andersen Capital are hosting a digital event where you can meet and ask questions directly to the top management. It is free for all to attend.InDex Pharmaceuticals - Positive feedback form Japanese authorities (PDMA) for CobitolimodMeet and ask questions to Acting CEO Johan Gileus from InDex Pharmaceuticals and CMO Anders Bröjersen who will update us on the announcement regarding Cobitolimod in Japan.The phase 3 program – Conclude, consists of two sequential global induction studies and a year-long maintenance study. The first phase 3 study of Conclude is ongoing and results are

Lynparza approved in China for ovarian cancer

22 September 2022 07:00 BST Lynparza approved in China as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer One in two women with advanced ovarian cancer has an HRD-positive tumour AstraZeneca and MSD's Lynparza (olaparib) has been approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to 1st-line platinum-based chemotherapy in combination with bevacizumab, and whose cancer is associated with homologous recombination

Fabege´s nominating committe for the AGM 2023

The Nomination Committee consists of the following members: · Göran Hellström, Chairman and representative for Backahill AB. · Suzanne Sandler, representative for Handelsbanken funds. · Eva Gottfridsdotter-Nilsson, representative for Länsförsäkringar funds. · Andreas Hofmann, representative for the Qviberg family.Fabege’s Annual General Meeting 2022 adopted terms of reference for the structure of the Nominating Committee. According to these, the company shall have a Nominating Committee consisting primarily of one representative of each of the four largest shareholders in

Konftel 800 Speakerphone Gains New ‘Lecture Mode’ Boost

Konftel’s flagship conferencing speakerphone has been boosted by a new ‘lecture mode’ wireless headset feature, which creates more user freedom especially for teaching and training.The Konftel 800 is now capable of linking to an approved wireless headset – to provide a teacher or presenter with total freedom of movement and position within a room. “Wherever they are located, perhaps facing a whiteboard, they can still have perfect microphone pick-up and be heard clearly by all remote participants,” says Konftel Product Manager, Torbjörn Karlsson. “We are delighted to announce the

CapMan Special Situations invests in Niemi Services, the leading moving and logistics services provider in Finland

CapMan Special Situations press release22 September 2022 at 09:00 AM EEST CapMan Special Situations invests in Niemi Services, the leading moving and logistics services provider in Finland The CapMan Special Situations Fund invests in Niemi Services and will support the company’s’ growth as the leading provider of moving and logistics services in Finland. In connection to the investment made by the CapMan Special Situations Fund, two of the company’s current owners, Ilpo and Kai Niemi, sell their shares in the company. Esa and Juha Niemi continue as main owners of the company and

Metso Outotec to deliver Planet Positive equipment package to G Mining Ventures’ Tocantinzinho Gold Project in Brazil

Metso Outotec Corporation’s press release on September 22, 2022, at 09:00 a.m. EESTMetso Outotec has been awarded equipment orders by G Mining Ventures Corporation for the company’s flagship asset, the Tocantinzinho Gold Project, in Para State, Brazil. The value of the orders is approximately EUR 20 million, of which one fifth has been booked in Minerals’ third-quarter order intake and the rest in Minerals’ second-quarter orders received. Metso Outotec’s scope of delivery to the greenfield project consists of a compact aggregates plant and the key process equipment for the beneficiation

Green Investment Program planned at Kuusakoski

A new investment program will strengthen Kuusakoski´s position as a pioneer of the green transition in the recycling industry.  This will be a multi-year investment program which will enable Kuusakoski’s continued competitiveness and growth in the coming years. As an industrial recycler, Kuusakoski is at the forefront of the green transition. Recycling enables sustainable economic growth and is a solution to the global climate crisis with accompanied resource and energy scarcity. This creates a significant growth in demand for recycled materials. ”The investment program enables our

Hexagon's R-evolution launches venture capital arm to boost green-tech startups

Hexagon AB, a global leader in digital reality solutions combining sensor, software and autonomous technologies, today announced a new venture capital arm of R-evolution, the sustainable innovation and green-tech investment subsidiary of Hexagon.Today’s climate emergencies demand urgent investments in innovative, planet-saving initiatives. It is up to all industries to decisively address the crisis while supporting economic growth and green-tech startups are a critical part of the solution. The R-ventures programme aims to help the green-tech startup ecosystem accelerate its next

Invitation to ASSA ABLOY’s Capital Markets Day on 16 November 2022 in London

ASSA ABLOY invites investors, analysts and financial media to its Capital Markets Day (CMD) on 16 November 2022 in London, UK. The event will start at 08.30 GMT and is expected to finish around 16.00 GMT. During the CMD in London, there will be the opportunity to informally meet and talk with all participating representatives from ASSA ABLOY. We will also be displaying interesting products and solutions, including from Entrance Systems, HID and EMEIA. At the CMD, Nico Delvaux, President and CEO, and Erik Pieder, CFO, will provide an update on ASSA ABLOY’s strategy and direction. Other

Grant of Options

Faron Pharmaceuticals Ltd (“Faron” or the “Company”)   Grant of options   Company announcement, September 22, 2022 at 09:00 AM (EEST) / 07:00 AM (BST) / 02:00 AM (EST)   TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces that the Board of Faron has confirmed the grant of a total of 129,000 options options over ordinary shares in the Company (“Options”)

Norse Atlantic Airways H1 2022 results

Norse Atlantic Airways today reported its H1 results. The first half of 2022 marked a milestone in Norse Atlantic’s history as it flew its first commercial flight, just over a year after the Company was formed.Norse launched its ticket sales on 29 April 2022 and the first flight took off on 14 June 2022 from Oslo to New York, followed by flights to Fort Lauderdale and, post-quarter end, to London, Orlando, Los Angeles and Berlin. “Our inaugural flight from Oslo to New York marked a milestone for Norse Atlantic Airways. The company achieved a load factor of 82 per cent for June which

Norse Atlantic Airways begins trading on OTCQX Market

Arendal, Norway – 22nd September 2022 – Norse Atlantic Airways is pleased to announce that the company will begin trading today on the OTCQX® Best Market in New York. Trading will commence at 09.00 EST / 15.00 CET.OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. “We are very pleased to have begun trading on the OTCQX Market. This will allow both large and small US investors to more easily trade in Norse Atlantic Airways and be part of our journey to democratize long haul transatlantic travel by offering affordable fares

Composition of SRV Group Plc’s Shareholders’ Nomination Board

SRV GROUP PLC     STOCK EXCHANGE RELEASE     22 SEPTEMBER 2022     9:00 EEST Composition of SRV Group Plc’s Shareholders’ Nomination BoardSRV Group Plc’s Annual General Meeting in 2020 decided to establish a Shareholders’ Nomination Board. The Nomination Board prepares proposals concerning the composition and remuneration of the Board of Directors to the Annual General Meeting. The Shareholders’ Nomination Board comprises of four members appointed by the three largest shareholders of the company. The Chairman of the Board of Directors shall act as the fourth member of the Board.

Vicore announces that C21 promotes vascular function in humans

· Clinically relevant doses of C21 increase blood flow in humans · Systemic blood pressure was unaffected, and no side effects were observed · The forearm blood flow method is a robust technique for early clinical concept testing Gothenburg, September 22, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines stimulating the angiotensin II type 2 receptor (AT2R), today announces that intra-arterial administration of C21 results in a significant dose-dependent increase in local blood flow.  Forearm blood flow was measured

BioStock: Idogen's transformation to clinical phase with IDO 8

Recently, the biotech company Idogen received approval from the ethics committee in Oslo for the clinical phase I/IIa study with the cell therapy within the IDO 8 programme in patients with haemophilia A. In addition, the company is preparing to obtain approval to start the study in countries other than Sweden and Norway. BioStock had a chat with Hanjing Xie, CMO, about the study and her time in the company.Read the full article at biostock.se: https://www.biostock.se/en/2022/09/idogens-transformation-to-clinical-phase-with-ido8/ This is a press release from BioStock - Connecting

There are no items matching the current filter
There are no more items matching the current filter
Back to top